Announced details
Treatment of severe heart failure, domestic commercialization and launch
Our company applied to the Tokyo Metropolitan Government for a license to manufacture and market regenerative medicine products and obtained the license from the Tokyo Metropolitan Government.
Tokyo Metropolitan Government. The application and licensing authority for a license to manufacture and market regenerative medicine products. Other details: Not disclosed
License to market regenerative medical products
Tokyo Metropolitan Government
No revision has been made to the earnings forecast for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Allogeneic iPS cell-derived cardiac spheroids for severe heart failure |
| Counterparty | Tokyo Metropolitan Government |
| Counterparty overview | Tokyo Metropolitan Government. The application and licensing authority for a license to manufacture and market regenerative medicine products. Other details: Not disclosed |
| Relationship with the Company | Our company applied to the Tokyo Metropolitan Government for a license to manufacture and market regenerative medicine products and obtained the license from the Tokyo Metropolitan Government. |
| Applicable area | Treatment of severe heart failure, domestic commercialization and launch |
| Award/certification name | License to market regenerative medical products |
| Awarding / certifying body | Tokyo Metropolitan Government |
| Impact on Business Performance | No revision has been made to the earnings forecast for the fiscal year ending December 2026. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate the establishment of a practical framework for future domestic commercialization and launch, and to promote compliance with laws and regulations governing pharmaceuticals and related products.